医学
突变体
抗体-药物偶联物
曲妥珠单抗
表皮生长因子受体
结合
肺癌
内科学
癌症研究
肿瘤科
抗体
单克隆抗体
癌症
生物
乳腺癌
免疫学
基因
遗传学
数学
数学分析
作者
Bob T. Li,Egbert F. Smit,Yasushi Goto,Kazuhiko Nakagawa,Hibiki Udagawa,Julien Mazières,Misako Nagasaka,Lyudmila Bazhenova,Andreas Saltos,Enriqueta Felip,Jose M. Pacheco,Maurice Pérol,Luis Paz‐Ares,Kapil Saxena,R. Shiga,Yun Cheng,Suddhasatta Acharyya,Patrik Vitazka,Javad Shahidi,David Planchard,Pasi A. Jänne
标识
DOI：10.1056/nejmoa2112431
摘要
Human epidermal growth factor receptor 2 (HER2)–targeted therapies have not been approved for patients with non–small-cell lung cancer (NSCLC). The efficacy and safety of trastuzumab deruxtecan (formerly DS-8201), a HER2 antibody–drug conjugate, in patients with HER2-mutant NSCLC have not been investigated extensively.
科研通智能强力驱动
Strongly Powered by AbleSci AI
爱静静
加菲丰丰
有人
shinysparrow
Singularity
寻道图强
可口可乐了
乐乐乐乐乐乐
景辣条
充电宝
精明元霜
mmyhn
AireenBeryl531
星辰大海
kento
贰鸟
Cindy
浅尝离白
sirius
Lucas
皖公网安备34019202002308
